59P Long term survival data from all recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients treated with MVX-ONCO-1 during open-labelled phase I and phase IIa clinical trials

Background: CAR T cell therapies have shown success in cancer treatment, especially in hematologic malignancies.However, scalability, manufacturing, and inpatient treatment limit their broad use.A non-viral, off-the-shelf solution is key to overcoming these barriers, especially for indications outside oncology.Building on mRNA LNPs for in-vivo CAR T delivery, we developed SENDER (Specific Engager Nanoparticle DelivERy), a novel approach to redirect LNPs for targeted mRNA delivery to immune cells.SENDER proteins non-covalently bind to LNPs, redirect them to T cells, and block protein corona formation, reducing off-target accumulation in the liver. Methods:The SENDER technology delivers LNP to T cells, ensuring specific mRNA delivery while preventing off-target accumulation.The design was tested both in vitro, for its ability to deliver mRNA payloads to T cells, and in vivo, using a humanized mouse model to evaluate tumor clearance and CAR T cell expression.